Tight-binding inhibitors-IV. Inhibition of adenosine deaminases by various inhibitors

Ram P. Agarwal, Thomas Spector, Robert E. Parks

Research output: Contribution to journalArticle

345 Citations (Scopus)

Abstract

Three ADA (adenosine deaminase) inhibitors, DHMPR (1,6-dihydro-6-hydroxymethyl purine ribonucleoside); EHNA [erythro-9-(2-hydroxy-3 nonyl)adenine] ; and deoxycoformycin [(R)-3-(2-deoxy-β-d-erythro-pento-furanosyl)-3, 6,7,8-tetrahydroimidazo[4,5-d] [1,3-diazepin-8-ol] or Covidarabin, were compared with regard to their inhibitory behavior with ADAs from human erythrocytes and calf intestine. Marked differences in the times required for establishment of steady state between the enzyme and inhibitors were observed, e.g. DHMPR, virtually instantaneous; EHNA, 2-3 min; and deoxycoformycin, many hr. The parameters of the inhibition of human erythrocytic ADA by deoxycoformycin were as follows: the association rate constant (k1) = 2.6 × 106 M-1 sec-1 ; the dissociation rate constant of the enzyme-inhibitor complex (k2) = 6.6 × 10-6 sec-1; Ki (from k2 k1) = 2.5 × 10-12M and Ki (from I50) = 1.5 × 10-11 M. The Ki values for EHNA and DHMPR, as determined by classical methods after attainment of steady state, were 1.6 × 10-9 and 1.3 × 10-6 M, respectively, for human erythrocytic ADA. The kinetic parameters for EHNA and calf intestinal ADA were as follows: Ki = 6.5 × 10-9 M (by the method of I50); k1 = 0.7 × 106 M-1 sec-1' and k2 = 4.6 × 10-3 sec-1. On the basis of Ki values, the inhibitors. DHMPR, EHNA and deoxycoformycin (a transition state analog), were classified as readily reversible, semi-tight-binding and tight-binding inhibitors. The difficulties encountered in the kinetic analyses of different types of inhibitors and the methods for dealing with the problems of these inhibitors are discussed.

Original languageEnglish
Pages (from-to)359-367
Number of pages9
JournalBiochemical Pharmacology
Volume26
Issue number5
DOIs
StatePublished - Mar 1 1977
Externally publishedYes

Fingerprint

Adenosine Deaminase Inhibitors
Pentostatin
Adenosine Deaminase
Enzyme Inhibitors
Rate constants
Kinetic parameters
Intestines
9-(2-hydroxy-3-nonyl)adenine
Inhibition (Psychology)
Erythrocytes
Association reactions
Kinetics
nebularine

ASJC Scopus subject areas

  • Pharmacology

Cite this

Tight-binding inhibitors-IV. Inhibition of adenosine deaminases by various inhibitors. / Agarwal, Ram P.; Spector, Thomas; Parks, Robert E.

In: Biochemical Pharmacology, Vol. 26, No. 5, 01.03.1977, p. 359-367.

Research output: Contribution to journalArticle

Agarwal, Ram P. ; Spector, Thomas ; Parks, Robert E. / Tight-binding inhibitors-IV. Inhibition of adenosine deaminases by various inhibitors. In: Biochemical Pharmacology. 1977 ; Vol. 26, No. 5. pp. 359-367.
@article{083f76a05f304c599dbad3ac2c0cb228,
title = "Tight-binding inhibitors-IV. Inhibition of adenosine deaminases by various inhibitors",
abstract = "Three ADA (adenosine deaminase) inhibitors, DHMPR (1,6-dihydro-6-hydroxymethyl purine ribonucleoside); EHNA [erythro-9-(2-hydroxy-3 nonyl)adenine] ; and deoxycoformycin [(R)-3-(2-deoxy-β-d-erythro-pento-furanosyl)-3, 6,7,8-tetrahydroimidazo[4,5-d] [1,3-diazepin-8-ol] or Covidarabin, were compared with regard to their inhibitory behavior with ADAs from human erythrocytes and calf intestine. Marked differences in the times required for establishment of steady state between the enzyme and inhibitors were observed, e.g. DHMPR, virtually instantaneous; EHNA, 2-3 min; and deoxycoformycin, many hr. The parameters of the inhibition of human erythrocytic ADA by deoxycoformycin were as follows: the association rate constant (k1) = 2.6 × 106 M-1 sec-1 ; the dissociation rate constant of the enzyme-inhibitor complex (k2) = 6.6 × 10-6 sec-1; Ki (from k2 k1) = 2.5 × 10-12M and Ki (from I50) = 1.5 × 10-11 M. The Ki values for EHNA and DHMPR, as determined by classical methods after attainment of steady state, were 1.6 × 10-9 and 1.3 × 10-6 M, respectively, for human erythrocytic ADA. The kinetic parameters for EHNA and calf intestinal ADA were as follows: Ki = 6.5 × 10-9 M (by the method of I50); k1 = 0.7 × 106 M-1 sec-1' and k2 = 4.6 × 10-3 sec-1. On the basis of Ki values, the inhibitors. DHMPR, EHNA and deoxycoformycin (a transition state analog), were classified as readily reversible, semi-tight-binding and tight-binding inhibitors. The difficulties encountered in the kinetic analyses of different types of inhibitors and the methods for dealing with the problems of these inhibitors are discussed.",
author = "Agarwal, {Ram P.} and Thomas Spector and Parks, {Robert E.}",
year = "1977",
month = "3",
day = "1",
doi = "10.1016/0006-2952(77)90192-7",
language = "English",
volume = "26",
pages = "359--367",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Tight-binding inhibitors-IV. Inhibition of adenosine deaminases by various inhibitors

AU - Agarwal, Ram P.

AU - Spector, Thomas

AU - Parks, Robert E.

PY - 1977/3/1

Y1 - 1977/3/1

N2 - Three ADA (adenosine deaminase) inhibitors, DHMPR (1,6-dihydro-6-hydroxymethyl purine ribonucleoside); EHNA [erythro-9-(2-hydroxy-3 nonyl)adenine] ; and deoxycoformycin [(R)-3-(2-deoxy-β-d-erythro-pento-furanosyl)-3, 6,7,8-tetrahydroimidazo[4,5-d] [1,3-diazepin-8-ol] or Covidarabin, were compared with regard to their inhibitory behavior with ADAs from human erythrocytes and calf intestine. Marked differences in the times required for establishment of steady state between the enzyme and inhibitors were observed, e.g. DHMPR, virtually instantaneous; EHNA, 2-3 min; and deoxycoformycin, many hr. The parameters of the inhibition of human erythrocytic ADA by deoxycoformycin were as follows: the association rate constant (k1) = 2.6 × 106 M-1 sec-1 ; the dissociation rate constant of the enzyme-inhibitor complex (k2) = 6.6 × 10-6 sec-1; Ki (from k2 k1) = 2.5 × 10-12M and Ki (from I50) = 1.5 × 10-11 M. The Ki values for EHNA and DHMPR, as determined by classical methods after attainment of steady state, were 1.6 × 10-9 and 1.3 × 10-6 M, respectively, for human erythrocytic ADA. The kinetic parameters for EHNA and calf intestinal ADA were as follows: Ki = 6.5 × 10-9 M (by the method of I50); k1 = 0.7 × 106 M-1 sec-1' and k2 = 4.6 × 10-3 sec-1. On the basis of Ki values, the inhibitors. DHMPR, EHNA and deoxycoformycin (a transition state analog), were classified as readily reversible, semi-tight-binding and tight-binding inhibitors. The difficulties encountered in the kinetic analyses of different types of inhibitors and the methods for dealing with the problems of these inhibitors are discussed.

AB - Three ADA (adenosine deaminase) inhibitors, DHMPR (1,6-dihydro-6-hydroxymethyl purine ribonucleoside); EHNA [erythro-9-(2-hydroxy-3 nonyl)adenine] ; and deoxycoformycin [(R)-3-(2-deoxy-β-d-erythro-pento-furanosyl)-3, 6,7,8-tetrahydroimidazo[4,5-d] [1,3-diazepin-8-ol] or Covidarabin, were compared with regard to their inhibitory behavior with ADAs from human erythrocytes and calf intestine. Marked differences in the times required for establishment of steady state between the enzyme and inhibitors were observed, e.g. DHMPR, virtually instantaneous; EHNA, 2-3 min; and deoxycoformycin, many hr. The parameters of the inhibition of human erythrocytic ADA by deoxycoformycin were as follows: the association rate constant (k1) = 2.6 × 106 M-1 sec-1 ; the dissociation rate constant of the enzyme-inhibitor complex (k2) = 6.6 × 10-6 sec-1; Ki (from k2 k1) = 2.5 × 10-12M and Ki (from I50) = 1.5 × 10-11 M. The Ki values for EHNA and DHMPR, as determined by classical methods after attainment of steady state, were 1.6 × 10-9 and 1.3 × 10-6 M, respectively, for human erythrocytic ADA. The kinetic parameters for EHNA and calf intestinal ADA were as follows: Ki = 6.5 × 10-9 M (by the method of I50); k1 = 0.7 × 106 M-1 sec-1' and k2 = 4.6 × 10-3 sec-1. On the basis of Ki values, the inhibitors. DHMPR, EHNA and deoxycoformycin (a transition state analog), were classified as readily reversible, semi-tight-binding and tight-binding inhibitors. The difficulties encountered in the kinetic analyses of different types of inhibitors and the methods for dealing with the problems of these inhibitors are discussed.

UR - http://www.scopus.com/inward/record.url?scp=0017360775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017360775&partnerID=8YFLogxK

U2 - 10.1016/0006-2952(77)90192-7

DO - 10.1016/0006-2952(77)90192-7

M3 - Article

C2 - 849330

AN - SCOPUS:0017360775

VL - 26

SP - 359

EP - 367

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 5

ER -